{"id":1194,"date":"2019-02-01T14:14:48","date_gmt":"2019-02-01T13:14:48","guid":{"rendered":"http:\/\/haavind.local\/en\/2019\/02\/01\/pharma-report-winter-2019\/"},"modified":"2022-07-21T12:51:18","modified_gmt":"2022-07-21T12:51:18","slug":"pharma-report-winter-2019","status":"publish","type":"post","link":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/","title":{"rendered":"The Haavind Pharma Report Winter 2019"},"content":{"rendered":"\t
\n\t\t
\n\t\t\t
\n\t\t\t\t

The Haavind Pharma Report Winter 2019<\/h1>\n\n

In the Pharma Report Winter 2019, we take a retrospective view on some of the legal developments during the second half of 2018 in the Norwegian pharmaceutical sector.<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t

<\/div>\n\t\t\t\t\t
\n\t\t\t\t\t\t01 February, 2019 \u00b7 3 min. reading time<\/span>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\n
\n\t\t\t\tWritten by<\/span>\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\n\t\t\t\t\t\t
\n\t\t\t\t\t\tH\u00e5kon Austdal<\/span>\n\t\t\t\t\t\tSpecialist Counsel<\/span>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/a>\n\t\t\t\t\t
\n\t\t\t\t\t\t\n\t\t\t\t\t\t
\n\t\t\t\t\t\tVebj\u00f8rn Krag Iversen<\/span>\n\t\t\t\t\t\tPartner<\/span>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/a><\/div>\n\t\t\t\t
\n\t\t\t\tTopics<\/span>\n\t\t\t\t
Dispute resolution<\/a>Intellectual property rights<\/span>Healthcare and life science<\/span><\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n

In the Pharma Report Winter 2019, we take a retrospective view on some of the legal developments during the second half of 2018 in the Norwegian pharmaceutical sector.<\/p>\n\n\n

The second half of 2018 continued to be as eventful as the first for legal practitioners in the pharmaceutical sector, particularly from a regulatory standpoint. We are therefore pleased to present a retrospective view on some of these legal developments.<\/p>\n\n\n\n

In this edition of our biannual report, you can read about part two of AstraZeneca\u2019s challenge of the Norwegian Medicines Agency\u2019s decision to subject its blockbuster inhaler medicine to generic substitution. You can also read about the proposed amendments on the rules on pharmaceutical advertising and the recent development on administrative fines for breaches of pharmaceutical law.<\/p>\n\n\n\n

From an IP-perspective, this edition of Pharma Report provides an overview of the case between Teva \/ Actavis and Novartis on the validity of the Exforge-patent.<\/p>\n\n\n\n

Read the Pharma Report Winter 2019 here<\/strong><\/a> (e-book)<\/p>\n\n\n\n

Download the Pharma Report Winter 2019 here<\/strong><\/a> (PDF)<\/p>\n\n\n

\"Pharma
Pharma Report Winter 2019<\/figcaption><\/figure><\/div>\n\n\n

Haavind\u2019s Health and Life Science team continuously and closely monitors developments in Norway relevant to the pharma sector. If you wish to discuss how your business can best meet the legal challenges of this innovative and highly regulated sector, you are always welcome to contact us.<\/em><\/p>\n\n\t

\n\t\t

Contact us<\/h2>\n\t\t
\n\t\t\t
\n
\n\t\n\t
\"\"<\/figure>\n\t<\/a>\n<\/div>\n\n\n
\n\t

Vebj\u00f8rn Krag Iversen<\/h2><\/a>\n\t
Partner<\/a><\/div>\n\t
v.iversen@haavind.stage01.dekodes.no<\/a><\/div>
+47 909 15 129<\/a><\/div><\/div>\n<\/div>\n\n<\/div>\n
\n
\n\t\n\t
\"\"<\/figure>\n\t<\/a>\n<\/div>\n\n\n
\n\t

H\u00e5kon Austdal<\/h2><\/a>\n\t
Specialist Counsel<\/a><\/div>\n\t
h.austdal@haavind.stage01.dekodes.no<\/a><\/div>
+47 920 19 526<\/a><\/div><\/div>\n<\/div>\n\n<\/div><\/div>\t\t<\/div>\n\t\t\t<\/div>\n\t","protected":false},"excerpt":{"rendered":"

In the Pharma Report Winter 2019, we take a retrospective view on some of the legal developments during the second half of 2018 in the Norwegian pharmaceutical sector.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"sector":[7],"speciality":[17,24],"acf":[],"yoast_head":"\nThe Haavind Pharma Report Winter 2019 - Haavind EN<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Haavind Pharma Report Winter 2019\" \/>\n<meta property=\"og:description\" content=\"In the Pharma Report Winter 2019, we take a retrospective view on some of the legal developments during the second half of 2018 in the Norwegian pharmaceutical sector.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/\" \/>\n<meta property=\"og:site_name\" content=\"Haavind EN\" \/>\n<meta property=\"article:published_time\" content=\"2019-02-01T13:14:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-21T12:51:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/medisin-monitor-scaled.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/\",\"url\":\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/\",\"name\":\"The Haavind Pharma Report Winter 2019 - Haavind EN\",\"isPartOf\":{\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/medisin-monitor-scaled.jpg\",\"datePublished\":\"2019-02-01T13:14:48+00:00\",\"dateModified\":\"2022-07-21T12:51:18+00:00\",\"author\":{\"@id\":\"\"},\"breadcrumb\":{\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/#primaryimage\",\"url\":\"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/medisin-monitor-scaled.jpg\",\"contentUrl\":\"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/medisin-monitor-scaled.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Intellectual property rights\",\"item\":\"https:\/\/haavind.stage01.dekodes.no\/en\/kompetanse\/fagomrade\/ipr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Haavind Pharma Report Winter 2019\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/#website\",\"url\":\"https:\/\/haavind.stage01.dekodes.no\/en\/\",\"name\":\"Haavind EN\",\"description\":\"-\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/haavind.stage01.dekodes.no\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Haavind Pharma Report Winter 2019 - Haavind EN","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/","og_locale":"en_US","og_type":"article","og_title":"The Haavind Pharma Report Winter 2019","og_description":"In the Pharma Report Winter 2019, we take a retrospective view on some of the legal developments during the second half of 2018 in the Norwegian pharmaceutical sector.","og_url":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/","og_site_name":"Haavind EN","article_published_time":"2019-02-01T13:14:48+00:00","article_modified_time":"2022-07-21T12:51:18+00:00","og_image":[{"url":"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/medisin-monitor-scaled.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/","url":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/","name":"The Haavind Pharma Report Winter 2019 - Haavind EN","isPartOf":{"@id":"https:\/\/haavind.stage01.dekodes.no\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/#primaryimage"},"image":{"@id":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/#primaryimage"},"thumbnailUrl":"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/medisin-monitor-scaled.jpg","datePublished":"2019-02-01T13:14:48+00:00","dateModified":"2022-07-21T12:51:18+00:00","author":{"@id":""},"breadcrumb":{"@id":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/#primaryimage","url":"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/medisin-monitor-scaled.jpg","contentUrl":"https:\/\/haavind.stage01.dekodes.no\/content\/uploads\/sites\/2\/2022\/06\/medisin-monitor-scaled.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/haavind.stage01.dekodes.no\/en\/pharma-report-winter-2019\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Intellectual property rights","item":"https:\/\/haavind.stage01.dekodes.no\/en\/kompetanse\/fagomrade\/ipr\/"},{"@type":"ListItem","position":2,"name":"The Haavind Pharma Report Winter 2019"}]},{"@type":"WebSite","@id":"https:\/\/haavind.stage01.dekodes.no\/en\/#website","url":"https:\/\/haavind.stage01.dekodes.no\/en\/","name":"Haavind EN","description":"-","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/haavind.stage01.dekodes.no\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/posts\/1194"}],"collection":[{"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/comments?post=1194"}],"version-history":[{"count":1,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/posts\/1194\/revisions"}],"predecessor-version":[{"id":3747,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/posts\/1194\/revisions\/3747"}],"wp:attachment":[{"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/media?parent=1194"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/categories?post=1194"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/tags?post=1194"},{"taxonomy":"sector","embeddable":true,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/sector?post=1194"},{"taxonomy":"speciality","embeddable":true,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/speciality?post=1194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}